Supporting International NASH Day
Posted: June 9, 2022
DiaPharma Supports International NASH Day
Heppy the Liver Man with his Finishers Medal
June 9, 2022 is International NASH Day (IND). IND is an initiative started by the Global Liver Institute to raise awareness of the growing worldwide epidemic of non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH).
There are currently no approved drugs to treat NAFLD or NASH, and following a lifestyle that includes a healthy diet and regular exercise – like going for a run – is still the best way to prevent and treat these diseases.
DiaPharma supports the development of pharmacological therapies for NASH by offering noninvasive tests (NITs) for biomarkers like CK18 that provide early, biologically plausible indications of changes in disease activity.
Visit us with VLVbio™ in the Biotech Village at the EASL International Liver Congress™ 2022
June 22 – 26 in London
DiaPharma offers additional non-invasive biomarker assays for NAFLD/NASH, AH, and DILI research. Incorporating these biomarkers into your research adds valuable information about changes in disease activity, which could decrease time and costs of studies. M30® and M65® Cytokeratin 18 (CK18) ELISAs, Intact Proinsulin, Osteopontin, Mac-2 Binding Protein, sCD163, L-FABP, FGF-19, and FGF-21 are just a few of the biomarker assays offered by DiaPharma to help your drug candidate move forward.
If you’d like to speak with an expert about which biomarker would be most useful for your project, call 800.447.3846 or email us today.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00930Rev01